Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor specific to the influenza virus, has the potential to be a game-changing, preventative therapy targeting a broad range of influenza strains, and could surpass $2B peak U.S. sales, the analyst tells investors in a research note. Cantor says that CD388 is designed to address many limitations of currently approved therapies, and that its active ingredient zanamivir has not been shown to acquire viral resistance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Announces Leadership Changes and Appointments
- Biotech Alert: Searches spiking for these stocks today
- Cidara Therapeutics files to sell 7.04M shares of common stock for holders
- Twelve option delistings on December 23rd
- Cidara Therapeutics initiated with an Outperform at RBC Capital